Dasatinib in the treatment of imatinib refractory chronic myeloid leukemia

by Radhakrishnan Ramchandren, Charles A Schiffer
Published 2009-05-01

Editorial: Advances in the treatment of Hodgkin lymphoma

by Matthew Mei, Guilherme Perini, Radhakrishnan Ramchandren
Published 2023-02-01

Phase 2 study of everolimus for relapsed or refractory classical Hodgkin lymphoma

by Patrick B. Johnston, Lauren C. Pinter-Brown, Ghulam Warsi, Kristen White, Radhakrishnan Ramchandren
Published 2018-05-01

Concurrent ibrutinib plus venetoclax in relapsed/refractory mantle cell lymphoma: the safety run-in of the phase 3 SYMPATICO study

by Michael Wang, Radhakrishnan Ramchandren, Robert Chen, Lionel Karlin, Geoffrey Chong, Wojciech Jurczak, Ka Lung Wu, Mark Bishton, Graham P. Collins, Paul Eliadis, Frédéric Peyrade, Yihua Lee, Karl Eckert, Jutta K. Neuenburg, Constantine S. Tam
Published 2021-10-01

The iR2 regimen (ibrutinib plus lenalidomide and rituximab) for relapsed/refractory DLBCL: a multicentre, non-randomised, open-label phase 2 studyResearch in context

by Radhakrishnan Ramchandren, Peter Johnson, Nilanjan Ghosh, Jia Ruan, Kirit M. Ardeshna, Roderick Johnson, Gregor Verhoef, David Cunningham, Sven de Vos, Shireen Kassam, Luis Fayad, John Radford, Sarah Bailly, Fritz Offner, David Morgan, Javier Munoz, Jerry Ping, Edith Szafer-Glusman, Karl Eckert, Jutta K. Neuenburg, Andre Goy
Published 2023-02-01

P009: Improved Overall Survival with First-Line Brentuximab Vedotin plus Chemotherapy in Patients with Advanced Stage III/IV Classical Hodgkin Lymphoma: An Updated Analysis of ECHE...

by Martin Hutchings, Stephen M. Ansell, Joseph M. Connors, Won Seog Kim, Andrea Gallamini, Radhakrishnan Ramchandren, Jonathan W. Friedberg, Ranjana Advani, Andrew M. Evens, Piotr Smolewski, Kerry J. Savage, Nancy L. Bartlett, Hyeon-Seok Eom, Jeremy S. Abramson, Cassie Dong, Frank Campana, Keenan Fenton, Markus Puhlmann, David J. Straus, John Radford
Published 2022-10-01